Full Papers
Two-year treatment persistence with subcutaneous abatacept in rheumatoid arthritis: results from the French cohort of the ASCORE study
R.-M. Flipo1, A. Constantin2, P. Goupille3, M. Chartier4, A. Ohayon5, X. Mariette6
- Rheumatology Department, Hôpital Salengro, Centre Hospitalier Universitaire Lille, Université de Lille, France.
- Rheumatology Department, Hôpital Pierre-Paul Riquet, Centre Hospitalier Universitaire Toulouse, France.
- Rheumatology Department, Centre Hospitalier Régional Universitaire de Tours, France.
- Global Clinical Trial Strategy and Operations Department, Bristol-Myers Squibb, Rueil‑Malmaison, France.
- Medical Immunology/Rheumatology, Bristol-Myers Squibb, Rueil-Malmaison, France. anael.ohayon@bms.com
- Rheumatology Department, Hôpital Bicêtre, Assistance Publique, Hôpitaux de Paris, Université Paris-Saclay, INSERM UMR1184, Le Kremlin‑Bicêtre, France.
CER17049
2024 Vol.42, N°7
PI 1377, PF 1386
Full Papers
Free to view
(click on article PDF icon to read the article)
PMID: 38436358 [PubMed]
Received: 07/08/2023
Accepted : 04/12/2023
In Press: 03/03/2024
Published: 18/07/2024
Abstract
OBJECTIVES:
While multiple studies have investigated treatment persistence rates with intravenous abatacept, limited information is available about real-world treatment continuation with the subcutaneous form. The international ASCORE study described the characteristics and treatment persistence of real-world patients with rheumatoid arthritis (RA) receiving subcutaneous abatacept. This article presents the findings of the French cohort.
METHODS:
This was an observational study in French RA patients who initiated subcutaneous abatacept between August 2014 and January 2017. The primary endpoint was treatment maintenance at 2 years, analysed according to the number of previous biologic therapies.
RESULTS:
Of 546 evaluable patients, 281 (51.5%) were biologic-naive, 265 (48.5%) had experienced failure with 1 (n=134; 24.5%) or ≥2 (n=131; 24.0%) biologic therapies. At enrolment, patients who had experienced failure with ≥1 biologic therapy had more erosions and a longer duration of RA compared with biologic-naive patients, but had comparable mean disease activity scores. Overall, 43.0% of patients (95% confidence interval 38.6–47.2) were still taking subcutaneous abatacept at 2 years, which was comparable with that in other countries participating in ASCORE. The abatacept persistence rate was higher in biologic-naive patients (48.8%) than in those with 1 (40.9%) or ≥2 (32.8%) biologic therapy failures. The main reason for discontinuing abatacept was lack of efficacy (46.6%).
CONCLUSIONS:
In current practice in France, the rate of subcutaneous abatacept persistence at 2 years was comparable with that of the intravenous form. Treatment persistence was higher when abatacept was used as first-line versus later-line biologic therapy.
